Lynn Seely is the founder of Myovant Sciences. Myovant Sciences has raised $1B in total funding. Latest round: IPO. Backed by Danippon Sumitomo Pharma.
Lynn Seely is the CEO of Myovant Sciences, a company dedicated to redefining care for women’s health and prostate cancer. Myovant Sciences has successfully raised $1 billion from investors, including Danippon Sumitomo Pharma, and executed one of the largest biopharma IPOs in 2016.
Full founder directory · Investor directory · Company funding database · Fundraising library